Vascular occlusive disease remains a critical cardiovascular health issue with about 500,000 percutaneous coronary and 50,000 peripheral balloon angioplasties performed annually in the US alone. Hemodynamically relevant restenoses through neointimal hyperplasia occur in 10 to 30% of patients. Vascular smooth muscle cell (VSMC) migration significantly contributes to neointimal hyperplasia after vascular injury. VSMC migration is a Ca2+-dependent process; migrating cells must maintain cytosolic Ca2+ gradients and create local Ca2+ pulses near the leading edge likely to accomplish dynamic cytoskeletal turnover. Mitochondria are one of the major buffers of intracellular Ca2+ in VSMC and participate in localized Ca2+ responses. In other cell types, cell migration is dependent upon mitochondrial localization to the leading edge. Thus, we propose that mitochondria provide localized control of Ca2+ transients, serving to facilitate VSMC migration. Previous work from our group established that the multifunctional Ca2+/calmodulin-dependent protein kinase II (CaMKII) is a key regulator of VSMC cell migration and proliferation. In more recent studies, we discovered that CaMKII is present and active in the mitochondrial matrix, where it is believed to promote mitochondrial matrix Ca2+ influx. In preliminary studies, mitoCaMKII inhibition in VSMC in a novel transgenic model developed in our laboratory blocks neointimal hyperplasia in vivo. Moreover, mitoCaMKII inhibition blocks mitochondrial Ca2+ uptake, mitochondrial mobility and VSMC migration. These data position mitochondrial CaMKII (mitoCaMKII) as a gatekeeper of mitochondrial function and of key VSMC phenotypes relevant for neointimal hyperplasia. In this this application, we will directly test our working hypothesis that mitoCaMKII inhibition blocks mitochondrial matrix Ca2+ uptake, thereby affecting mitochondrial mobility and VSMC migration and ultimately neointimal hyperplasia. We will test our working hypothesis in two aims: 1. Determine whether mitoCaMKII in VSMC controls neointimal formation through regulation of mitochondrial Ca2+ uptake and 2. Dissect the pathways and mechanisms by which mitoCaMKII controls VSMC migration. Studies will include in vivo analysis of neointimal formation using novel transgenic models of mitoCaMKII inhibition or overexpression and in vitro imaging of localized Ca2+ dysregulation, including ER/mitochondrial Ca2+ transition, Ca2+ waves and flickers as well as analysis of cytoskeleton and focal adhesion turnover. Moreover, novel pathways that link mitochondrial matrix Ca2+ uptake to VSMC migration will be tested. It is anticipated that the successful completion of the proposed studies will provide mechanistic insight into how changes in mitochondrial function lead to VSMC migration and neointimal formation. Such knowledge could lead to first-in-class, mitochondria- targeted therapies for vascular disease, in particular neointimal hyperplasia.

Public Health Relevance

The proposed research aims at understanding key mechanisms in the response to vascular injury with the ultimate goal of developing novel treatment strategies. It is relevant to public health because blood vessels respond to injury by forming blockages that can cause heart attacks and strokes, the most common causes of death in our nation. Thus, the proposed research is directly relevant to the part of the NIH?s mission that pertains to foster research strategies, and their applications as a basis for protecting and improving health.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL108932-08
Application #
9851422
Study Section
Vascular Cell and Molecular Biology Study Section (VCMB)
Program Officer
Gao, Yunling
Project Start
2012-04-16
Project End
2021-11-30
Budget Start
2019-12-01
Budget End
2020-11-30
Support Year
8
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Iowa
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Nguyen, Emily K; Koval, Olha M; Noble, Paige et al. (2018) CaMKII (Ca2+/Calmodulin-Dependent Kinase II) in Mitochondria of Smooth Muscle Cells Controls Mitochondrial Mobility, Migration, and Neointima Formation. Arterioscler Thromb Vasc Biol 38:1333-1345
Pennington, Steven M; Klutho, Paula R; Xie, Litao et al. (2018) Defective protein repair under methionine sulfoxide A deletion drives autophagy and ARE-dependent gene transcription. Redox Biol 16:401-413
Kulhankova, Katarina; Kinney, Kyle J; Stach, Jessica M et al. (2017) The Superantigen Toxic Shock Syndrome Toxin-1 Alters Human Aortic Endothelial Cell Function. Infect Immun :
Murthy, Shubha; Koval, Olha M; Ramiro Diaz, Juan M et al. (2017) Endothelial CaMKII as a regulator of eNOS activity and NO-mediated vasoreactivity. PLoS One 12:e0186311
Sebag, Sara C; Koval, Olha M; Paschke, John D et al. (2017) Mitochondrial CaMKII inhibition in airway epithelium protects against allergic asthma. JCI Insight 2:e88297
Winters, Christopher J; Koval, Olha; Murthy, Shubha et al. (2016) CaMKII inhibition in type II pneumocytes protects from bleomycin-induced pulmonary fibrosis by preventing Ca2+-dependent apoptosis. Am J Physiol Lung Cell Mol Physiol 310:L86-94
Gu, Sean X; Blokhin, Ilya O; Wilson, Katina M et al. (2016) Protein methionine oxidation augments reperfusion injury in acute ischemic stroke. JCI Insight 1:
Bosetti, Francesca; Galis, Zorina S; Bynoe, Margaret S et al. (2016) ""Small Blood Vessels: Big Health Problems?"": Scientific Recommendations of the National Institutes of Health Workshop. J Am Heart Assoc 5:
Prasad, Anand M; Ketsawatsomkron, Pimonrat; Nuno, Daniel W et al. (2016) Role of CaMKII in Ang-II-dependent small artery remodeling. Vascul Pharmacol 87:172-179
Klutho, Paula J; Pennington, Steven M; Scott, Jason A et al. (2015) Deletion of Methionine Sulfoxide Reductase A Does Not Affect Atherothrombosis but Promotes Neointimal Hyperplasia and Extracellular Signal-Regulated Kinase 1/2 Signaling. Arterioscler Thromb Vasc Biol 35:2594-604

Showing the most recent 10 out of 16 publications